Multiple Myeloma: Nuances of Minimal Residual Disease Diagnosis and Monitoring with the Use of Multicolor Flow Cytometry

AUTOIMMUNE THROMBOCYTOPENIA

IV Galtseva, KA Nikiforova, YuO Davydova, NM Kapranov, MV Solov’ev, EN Parovichnikova, LP Mendeleeva

National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Kseniya Aleksandrovna Nikiforova, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; Tel.: +7(495)612-62-21; e-mail: nikiforovaksenya@gmail.com

For citation: Galtseva IV, Nikiforova KA, Davydova YuO, et al. Multiple Myeloma: Nuances of Minimal Residual Disease Diagnosis and Monitoring with the Use of Multicolor Flow Cytometry. Clinical oncohematology. 2022;15(4):365–76. (In Russ).

DOI: 10.21320/2500-2139-2022-15-4-365-376

ABSTRACT

The assessment of minimal residual disease (MRD) by multicolor flow cytometry (MFC) is a rapidly growing area of laboratory studies. In recent years, it has become particularly valuable for hematologists. Although the MFC analysis of plasma cells in multiple myeloma patients is sufficiently standardized, there are differences in methods of sample preparation, monoclonal antibody combinations being used as well as in cytometric data evaluation. The present paper summarizes the key international and domestic data on the MFC analysis of plasma cells and documents the authors’ own experience with MFC analysis in multiple myeloma over the last few years.

Keywords: minimal residual disease, multiple myeloma, multicolor flow cytometry, gating, immunophenotyping.

Received: May 24, 2022

Accepted: August 10, 2022

Read in PDF

Статистика Plumx английский

REFERENCES

  1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. doi: 10.1016/S1470-2045(14)70442-5.
  2. Каприн А.Д., Старинский В.В., Шахзадова А.О. и др. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020.
    [Kaprin AD, Starinskii VV, Shakhzadova AO, et al. Zlokachestvennye novoobrazovaniya v Rossii v 2019 godu (zabolevaemost’ i smertnost’). (Malignant neoplasms in Russia in 2019 (incidence and mortality.) Moscow: MNIOI im. P.A. Gertsena — filial FGBU “NMITs radiologii” Publ.; 2020. (In Russ)]
  3. Соловьев М.В., Менделеева Л.П., Алексеева А.Н. и др. Эффективность терапии множественной миеломы в России (результаты многоцентрового проспективного исследования). Гематология и трансфузиология. 2020;65(1):103–4.
    [Solov’ev MV, Mendeleeva LP, Alekseeva AN, et al. The efficacy of multiple myeloma therapy in Russia (results of a multi-center prospective study). Gematologiya i transfuziologiya. 2020;65(1):103–4. (In Russ)]
  4. Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719–34. doi: 10.1002/ajh.24402.
  5. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346. doi: 10.1016/S1470-2045(16)30206-6.
  6. Paiva B, Vidriales M-B, Mateo G, et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood. 2009;114(20):4369–72. doi: 10.1182/blood-2009-05-221689.
  7. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540–7. doi: 10.1200/JCO.2012.46.2119.
  8. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–9. doi: 10.1182/blood-2014-01-550020.
  9. Korde N, Mailankody S, Roschewski M, et al. Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities. Blood. 2014;124(21):2105. doi: 10.1182/blood.V124.21.2105.2105.
  10. Avet-Loiseau H, Corre J, Lauwers-Cances V, et al. Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial. Blood. 2015;126(23):191. doi: 10.1182/blood.V126.23.191.191.
  11. Гальцева И.В., Менделеева Л.П., Давыдова Ю.О. и др. Исследование минимальной остаточной болезни методом многоцветной проточной цитофлуориметрии у больных множественной миеломой после трансплантации аутологичных гемопоэтических стволовых клеток. Онкогематология. 2017;12(2):62–9. doi: 10.17650/1818-8346-2017-12-2-62-69.
    [Galtseva IV, Mendeleeva LP, Davydova YuO, et al. Study of minimal residual disease by multicolor flow cytometry in multiple myeloma after autologous hematopoietic stem cell transplantation. Oncohematology. 2017;12(2):62–9. doi: 10.17650/1818-8346-2017-12-2-62-69. (In Russ)]
  12. Соловьев М.В., Менделеева Л.П., Покровская О.С. и др. Множественная миелома: поддерживающая терапия после трансплантации гемопоэтических стволовых клеток в зависимости от минимальной остаточной болезни. Терапевтический архив. 2017;89(7):25–31. doi: 10.17116/terarkh201789725-31.
    [Solovyev MV, Mendeleeva LP, Pokrovskaia OS, et al. Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease. Terapevticheskii arkhiv. 2017;89(7):25–31. doi: 10.17116/terarkh201789725-31. (In Russ)]
  13. Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988–99. doi: 10.1182/BLOODADVANCES.2020002827.
  14. Stetler-Stevenson M, Paiva B, Stoolman L, et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom. 2016;90(1):26–30. doi: 10.1002/cyto.b.21249.
  15. Менделеева Л.П., Вотякова О.М., Рехтина И.Г. и др. Множественная миелома: Клинические рекомендации [электронный документ]. Доступно по: https://cr.minzdrav.gov.ru/schema/144_1. Ссылка активна на 24.05.2022.
    [Mendeleeva LP, Votyakova OM, Rekhtina IG, et al. Multiple Myeloma: Clinical Guidelines [Internet]. Available from: https://cr.minzdrav.gov.ru/schema/144_1. Accessed 24.05.2022. (In Russ)]
  16. Менделеева Л.П., Покровская О.С. Множественная миелома. Клиническая онкогематология. 2009;2(1):96–8.
    [Mendeleeva LP, Pokrovskaya OS. Multiple myeloma. Klinicheskaya onkogematologiya. 2009;2(1):96–8. (In Russ)]
  17. Менделеева Л.П., Вотякова О.М., Покровская О.С. и др. Национальные клинические рекомендации по диагностике и лечению множественной миеломы. Гематология и трансфузиология. 2016;61(1, прил. 2):1–24. doi: 10.18821/0234-5730-2016-61-1-S2-1-24.
    [Mendeleeva LP, Votyakova OM, Pokrovskaya OS, et al. National clinical guidelines on diagnosis and treatment of multiple myeloma. Gematologiya i transfuziologiya. 2016;61(1, Suppl 2):1–24. doi: 10.18821/0234-5730-2016-61-1-S2-1-24. (In Russ)]
  18. Bergstrom DJ, Kotb R, Louzada ML, et al. Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium. Clin Lymphoma Myeloma Leuk. 2020;20(7):e352–e367. doi: 10.1016/j.clml.2020.01.017.
  19. Kumar SK, Callander NS, Adekola K, et al. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2020;18(12):1685–717. doi: 10.6004/jnccn.2020.0057.
  20. Perez-Persona E, Vidriales M-B, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586–92. doi: 10.1182/blood-2007-05-088443.
  21. Hogan KA, Chini CCS, Chini EN. The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases. Front Immunol. 2019;10:1187. doi: 10.3389/FIMMU.2019.01187.
  22. Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130(3):325–32. doi: 10.1111/j.1365-2141.2005.05550.x.
  23. Flores-Montero J, de Tute R, Paiva B, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016;90(1):61–72. doi: 10.1002/CYTO.B.21265.
  24. Bataille R, Jego G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica. 2006;91(9):1234–40.
  25. Tembhare PR, Yuan CM, Venzon D, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res. 2014;38(3):371–6. doi: 10.1016/J.LEUKRES.2013.12.007.
  26. Arroz M, Came N, Lin P, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90(1):31–9. doi: 10.1002/cyto.b.21228.
  27. Peceliunas V, Janiulioniene A, Matuzeviciene R, Griskevicius L. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B Clin Cytom. 2011;80B(5):318–23. doi: 10.1002/cyto.b.20601.
  28. Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431–8. doi: 10.3324/HAEMATOL.11080.
  29. Manasanch EE, Salem DA, Yuan CM, et al. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leuk Lymphoma. 2015;56(5):1416. doi: 10.3109/10428194.2014.955020.
  30. Stetler-Stevenson M, Ahmad E, Barnett D, et al. Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline, CLSI Document H43-A2. 2nd edn. Wayne: Clinical and Laboratory Standards Institute; 2007.
  31. Гальцева И.В., Давыдова Ю.О., Капранов Н.М. и др. Способ оценки качества аспирата костного мозга в процессе проведения мониторинга минимальной резидуальной болезни при множественной миеломе. Патент РФ № 2639382/21.12.2017. Бюлл. № 36. Доступно по: https://findpatent.ru/patent/263/2639382.html. Ссылка активна на 09.04.2022.
    [Galtseva IV, Davydova YuO, Kapranov NM, et al. Sposob otsenki kachestva aspirata kostnogo mozga v protsesse provedeniya monitoringa minimalnoi rezidualnoi bolezni pri mnozhestvennoi mielome. Patent RUS No. 2639382/21.12.2017. Byul. No. 36. Available from: https://findpatent.ru/patent/263/2639382.html. Accessed 09.04.2022. (In Russ)]
  32. Rawstron AC. Immunophenotyping of Plasma Cells. Curr Protoc Cytom. 2006;36(1). doi: 10.1002/0471142956.cy0623s36.
  33. Britt Z, O’Donahue M, Mills D. Surface staining for kappa and lambda, how many washes are sufficient? You might be surprised. Available from: http://www.cytometry.org/public/newsletters/eICCS-6–3/article2.php. (accessed 24.05.2022).
  34. Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–103. doi: 10.1038/LEU.2017.29.
  35. Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687–91. doi: 10.1182/blood-2011-07-370460.
  36. Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391–7. doi: 10.1038/leu.2013.217.